These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 38958627)
1. Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee. Madrid M; Lakshmipathy U; Zhang X; Bharti K; Wall DM; Sato Y; Muschler G; Ting A; Smith N; Deguchi S; Kawamata S; Moore JC; Makovoz B; Sullivan S; Falco V; Al-Riyami AZ Cytotherapy; 2024 Nov; 26(11):1382-1399. PubMed ID: 38958627 [TBL] [Abstract][Full Text] [Related]
2. Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies. Dashtban M; Panchalingam KM; Shafa M; Ahmadian Baghbaderani B Methods Mol Biol; 2021; 2286():179-198. PubMed ID: 32430594 [TBL] [Abstract][Full Text] [Related]
3. Bioprocessing considerations for generation of iPSCs intended for clinical application: perspectives from the ISCT Emerging Regenerative Medicine Technology working group. Song HW; Solomon JN; Masri F; Mack A; Durand N; Cameau E; Dianat N; Hunter A; Oh S; Schoen B; Marsh M; Bravery C; Sumen C; Clarke D; Bharti K; Allickson JG; Lakshmipathy U Cytotherapy; 2024 Nov; 26(11):1275-1284. PubMed ID: 38970614 [TBL] [Abstract][Full Text] [Related]
4. Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing. Yin X; Li Q; Shu Y; Wang H; Thomas B; Maxwell JT; Zhang Y J Biomed Sci; 2024 May; 31(1):47. PubMed ID: 38724973 [TBL] [Abstract][Full Text] [Related]
5. Large Animal Models for the Clinical Application of Human Induced Pluripotent Stem Cells. Cong X; Zhang SM; Ellis MW; Luo J Stem Cells Dev; 2019 Oct; 28(19):1288-1298. PubMed ID: 31359827 [TBL] [Abstract][Full Text] [Related]
9. Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges. Madrid M; Sumen C; Aivio S; Saklayen N Curr Protoc; 2021 Mar; 1(3):e88. PubMed ID: 33725407 [TBL] [Abstract][Full Text] [Related]
10. Manufacturing Parameters for the Creation of Clinical-Grade Human-Induced Pluripotent Stem Cell Lines From Umbilical Cord Mesenchymal Stromal Cells. Beckenkamp LR; da Silva CG; Von Hohendorff MLI; Ogliari KS Stem Cells Transl Med; 2024 May; 13(5):454-461. PubMed ID: 38402590 [TBL] [Abstract][Full Text] [Related]
11. Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation. Oikonomopoulos A; Kitani T; Wu JC Mol Ther; 2018 Jul; 26(7):1624-1634. PubMed ID: 29699941 [TBL] [Abstract][Full Text] [Related]
12. Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies. Nath SC; Menendez L; Friedrich Ben-Nun I Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069252 [TBL] [Abstract][Full Text] [Related]
13. Unlocking the Potential of Induced Pluripotent Stem Cells for Wound Healing: The Next Frontier of Regenerative Medicine. Dash BC; Korutla L; Vallabhajosyula P; Hsia HC Adv Wound Care (New Rochelle); 2022 Nov; 11(11):622-638. PubMed ID: 34155919 [No Abstract] [Full Text] [Related]
14. Future prospects for regenerated heart using induced pluripotent stem cells. Fujita J; Fukuda K J Pharmacol Sci; 2014; 125(1):1-5. PubMed ID: 24739283 [TBL] [Abstract][Full Text] [Related]
15. Induced Pluripotent Stem Cell-Derived Cardiomyocytes: From Regulatory Status to Clinical Translation. Soares CSP; Ribeiro MHL Tissue Eng Part B Rev; 2024 Aug; 30(4):436-447. PubMed ID: 38149607 [TBL] [Abstract][Full Text] [Related]
16. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Sullivan S; Stacey GN; Akazawa C; Aoyama N; Baptista R; Bedford P; Bennaceur Griscelli A; Chandra A; Elwood N; Girard M; Kawamata S; Hanatani T; Latsis T; Lin S; Ludwig TE; Malygina T; Mack A; Mountford JC; Noggle S; Pereira LV; Price J; Sheldon M; Srivastava A; Stachelscheid H; Velayudhan SR; Ward NJ; Turner ML; Barry J; Song J Regen Med; 2018 Oct; 13(7):859-866. PubMed ID: 30205750 [TBL] [Abstract][Full Text] [Related]
17. Overcoming the challenges of scalable iPSC generation in translation medicine. Liu DH; Tseng HC; Lee MS; Chiou GY; Wang CT; Lin YY; Lai WY; Liu YH; Wang CY; Lee CY; Kao CL; Chen CF; Chien Y J Chin Med Assoc; 2024 Feb; 87(2):163-170. PubMed ID: 38132887 [TBL] [Abstract][Full Text] [Related]
18. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Jha BS; Farnoodian M; Bharti K Stem Cells Transl Med; 2021 Feb; 10(2):198-208. PubMed ID: 32946199 [TBL] [Abstract][Full Text] [Related]
19. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies. Azuma K; Yamanaka S Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486 [TBL] [Abstract][Full Text] [Related]
20. Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy. Sun C; Serra C; Kalicharan BH; Harding J; Rao M Cells; 2024 Mar; 13(7):. PubMed ID: 38607035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]